About BASIS

All cancers arise due to somatically acquired mutations in their genomes which alter the function of key cancer genes. Understanding these critical mutational events underlying cancer development is paramount for advancing prevention, early detection, monitoring and treatment of the disease. Breast cancer is the most common class of cancer diagnosed in women worldwide with more than one million cases diagnosed annually. It is responsible for 400,000 deaths per year making it the leading cause of cancer deaths in women and is the most common cause of all deaths in women aged >40 years.

The strategy of BASIS is to collect, store, review, quality control and extract DNA and RNA from breast cancer and normal tissues from 500 ER+, HER2- breast cancer cases which will be subjected to a coordinated series of genomic analyses including whole genome shotgun sequencing, genome-wide copy number analysis, mRNA expression analysis, miRNA expression analysis and genome-wide methylation analysis. A comprehensive catalogue of somatic mutations will be generated from each cancer. Somatic mutation catalogues from the 500 cancers will be analysed and integrated with expression and methylation data to identify novel cancer genes, characterise subverted biological pathways that are operative, describe patterns of somatic mutation and explore early translational applications of personalised somatic genomic data for patients with ER+, HER2- breast cancer.

Cookies policy | Terms & Conditions. This site is hosted by the Wellcome Trust Sanger Institute.